UPDATE: Imprimis CEO Mark Baum Tells Benzinga Eton Spin-Off Will Respond To FDA Pharma Competition Concerns, Improve Competition Against 2 'Expensive drugs without competition: Mallinckrodt's H.P. Acthar gel and Endo's Xiaflex'